Fundraising FoxGRIP Molecular Technologies
Saint Paul, US · Founded 2019 · Delaware corporation
Find your way into GRIP Molecular Technologies
Sign up to see every warm intro you have to GRIP Molecular Technologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the GRIP Molecular Technologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
GRIP Molecular Technologies develops a diagnostic platform built on a CRISPR protease engine that detects pathogen RNA (bacteria, viruses, fungi) from saliva, swab, and urine samples with molecular-grade accuracy in minutes at ambient temperature. It targets point-of-care and point-of-need testing for sexually transmitted, urinary tract, and upper respiratory infections, adaptable to lateral flow, electrochemical, and colorimetric readouts.
Founders & leadership
EG
Edward GillenCEO | CCOHe brings over 30 years of medical device leadership experience across diabetes, vascular surgery, ophthalmology, and anesthesia, with expertise in drug delivery, digital health, point-of-care diagnostics, and surgical devices.
RM
Richard MinicusCFO
BB
Bruce BattenFounder | CSOBruce Batten founded GRIP Molecular Technologies in 2019 and serves as its President and Chief Scientific Officer. He has a background in cell and molecular biology, molecular diagnostics, biosensing, and infectious disease, with prior experience in molecular diagnostics startups.
Board
EL
Edward LudwigBoard Chairman
MO
Michael OsterholmClinical Advisor
Reported raises · per SEC filings
Form D private placements$9.4M disclosed across 3 rounds · 2019–2023
▶$8.8MraisedMay 2025 · 41 investors · Other TechnologyRule 506(b)
▶$8.8MraisedMay 2025 · 41 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Edward GillenExecutive Officer
- Richard MinicusExecutive Officer
- Bruce BattenExecutive Officer, Director
- Edward LudwigDirector
- Offering amount
- $12M
- Amount sold
- $8.8M
- Minimum investment
- $10K
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedMay 2023 · 1 investors · Other TechnologyRule 506(b)
▶$500KraisedMay 2023 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Bruce BattenExecutive Officer, Director
- Richard MinicusExecutive Officer
- Edward GillenExecutive Officer
- Edward LudwigDirector
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $500K
- First sale
- May 2023
- Incorporated
- Corporation, Minnesota, 2019
- Federal exemptions
- 06b
▶$100KraisedDec 2020 · 1 investors · Other TechnologyRule 506(b)
▶$100KraisedDec 2020 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Edward GillenExecutive Officer
- Bruce BattenDirector
- Amount sold
- $100K
- First sale
- Nov 2020
- Incorporated
- Corporation, Minnesota, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
CepheidCepheid manufactures molecular diagnostic instruments and tests that automate PCR-based testing for infectious diseases, oncology, and human genetics. The company serves institutions ranging from central laboratories to near-patient settings with automated diagnostic solutions.
MediaroomMediaRoom is a PR Newswire product that builds branded, fully-hosted online newsrooms for organizations to publish press releases, media coverage, images and videos in one place for journalists, investors and other audiences. It offers custom microsite design, automatic press release posting, social media integration, a content management portal, and SOC 2-compliant hosting with analytics.
Companies working in the same space as GRIP Molecular Technologies.
In the news
Frequently asked questions
- What does GRIP Molecular Technologies do?
- GRIP Molecular Technologies develops a diagnostic platform built on a CRISPR protease engine that detects pathogen RNA (bacteria, viruses, fungi) from saliva, swab, and urine samples with molecular-grade accuracy in minutes at ambient temperature. It targets point-of-care and point-of-need testing for sexually transmitted, urinary tract, and upper respiratory infections, adaptable to lateral flow, electrochemical, and colorimetric readouts.
- How much funding has GRIP Molecular Technologies raised?
- GRIP Molecular Technologies has disclosed $9.4M raised across 3 rounds.
- Where is GRIP Molecular Technologies headquartered?
- GRIP Molecular Technologies is headquartered in Saint Paul, US.